Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Costs and Expenses:
General and administrative	$ 1,500,000	$ 1,265,000	$ 3,155,000	$ 2,685,000
Research and development	3,485,000	1,932,000	6,082,000	3,049,000
Total Operating Costs and Expenses	4,985,000	3,197,000	9,237,000	5,734,000
Loss from Operations	(4,985,000)	(3,197,000)	(9,237,000)	(5,734,000)
Other Expense:
Exchange loss	(9,000)	0	(31,000)
Interest income	26,000	2,000	27,000	2,000
Total Other Income(Expense)	17,000	2,000	(4,000)	2,000
Net Loss	(4,968,000)	(3,195,000)	(9,241,000)	(5,732,000)
Net Loss Attributable to Non-controlling Interest	0	0		(1,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(4,968,000)	(3,195,000)	(9,241,000)	(5,731,000)
Effect of Series A Preferred Stock price adjustment			0	(7,402,000)
Net Loss Attributable to Common Stockholders	$ (4,968,000)	$ (3,195,000)	$ (9,241,000)	$ (14,654,000)
Net Loss Per Share - Basic	$ (0.31)	$ (0.24)	$ (0.62)	$ (1.31)
Net Loss Per Share - Dilutive	$ (0.31)	$ (0.24)	$ (0.62)	$ (1.31)
Weighted average number of shares outstanding during the period - basic	15,844,061	13,204,254	14,837,832	11,153,902
Weighted average number of shares outstanding during the period - dilutive	15,844,061	13,204,254	14,837,832	11,153,902
Series A Preferred Stock [Member]
Other Expense:
Preferred Stock Dividends, Income Statement Impact	$ 0	$ 0		$ (24,000)
Effect of Series A Preferred Stock price adjustment	0	0		(7,402,000)
Series B Preferred Stock [Member]
Other Expense:
Net Loss Attributable to Non-controlling Interest				100,000
Preferred Stock Dividends, Income Statement Impact	0	0		$ (1,497,000)
Preferred Stock [Member] | Series B Preferred Stock [Member]
Other Expense:
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ 0	$ 0